The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
Document Type
Journal Article
Publication Date
4-20-2017
Journal
Clinical Cancer Research : An Official Journal of the American Association for Cancer Research
DOI
10.1158/1078-0432.CCR-16-2895
APA Citation
Anderson, K., Auclair, D., Kelloff, G., Sigman, C., Avet-Loiseau, H., Farrell, A., Gormley, N., Kumar, S., Landgren, O., Munshi, N., Cavo, M., Davies, F., Di Bacco, A., Dickey, J., Gutman, S., Higley, H., Hussein, M., Jessup, J., Kirsch, I., Little, R., Loberg, R., Lohr, J., Mukundan, L., Omel, J., Pugh, T., Reaman, G., Robbins, M., Sasser, A., Valente, N., & Zamagni, E. (2017). The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, (). http://dx.doi.org/10.1158/1078-0432.CCR-16-2895
Peer Reviewed
1
